Accel-Orange City — Orange City, Florida

Accel-Orange City is a clinical research site located in Orange City, Florida, United States 32763.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Accel-Orange City has participated in 2 clinical trials.

Therapeutic areas: Migraine, Migraine With Aura, Migraine Without Aura.

Sponsors: Satsuma Pharmaceuticals, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Orange City

Browse all research sites in Florida · View every site in Orange City

• Florida Hospital Medical Group-Lake Mary Pediatrics
• Florida Hospital FISH
• Medical Research Group of Central Florida
• Mid Florida Hematology and Oncology Center
• Research Site
• Optimal Research Sites
• Florida Cancer Specialists
• Pfizer Investigational Site
• Mid-Florida Cancer Centers
• Lake Mary Pediatrics
• GSK Investigational Site
• Mid-Florida Hematology and Oncology Centers

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Accel-Orange City?

Accel-Orange City has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Accel-Orange City conducted?

Accel-Orange City has 2 clinical trials on record. Their work covers Migraine, Migraine With Aura, Migraine Without Aura.

Is Accel-Orange City accredited by Crixeo Clinical Trials?

Accel-Orange City has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Accel-Orange City?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.